MEI Pharma Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
LITS$0.95-6.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
Exhibit Index
| Incorporated by Reference Herein | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Schedule/Form | File No. | Exhibit | Filing Date |
| 2.1 | Asset Purchase Agreement, by and between MEI Pharma, Inc. and Aardvark Therapeutics, Inc., dated as of October 22, 2024. | 8-K | 001-41827 | 2.1 | October 25, 2022 |
| 3.1 | Certificate of Amendment of the Amended and Restated Certificate of Incorporation of MEI Pharma, Inc., filed with the Delaware Secretary of State on April 14, 2023 | 8-K | 000-50484 | 3.1 | April 14, 2023 |
| 3.2 | Sixth Amended and Restated Bylaws of MEI Pharma, Inc. adopted as of December 18, 2023 | 8-K | 001-41827 | 3.1 | December 22, 2023 |
| 3.3 | Certificate of Designation of Series A Convertible Preferred Stock of Marshall Edwards, Inc. | 8-K | 000-50484 | 3.1 | May 11, 2011 |
| 3.4 | Certificate of Designation of Series B Preferred Stock of Marshall Edwards, Inc. | 8-K | 000-50484 | 10.1 | March 18, 2011 |
| 3.5 | Certification of Designation of Series A Junior Participating Preferred Stock | 8-K | 000-50484 | 3.1 | October 3, 2023 |
| 4.1 | Specimen Stock Certificate | S-1 | 333-109129 | 4.1 | October 31, 2023 |
| 4.2 | Form of Warrant | 8-K | 000-50484 | 10.1 | May 16, 2018 |
| 10.1+ | Addendum to Employment Agreement between MEI Pharma, Inc. and Justin J. File, dated August 1, 2024 | 10-K | 000-50484 | 10.24 | September 19, 2024 |
| 10.2* | Separation and Release Agreement, dated as of August 3, 2024, by and between MEI Pharma, Inc. and Richard G. Ghalie | ||||
| 10.3* | Separation and Release Agreement, dated as of August 4, 2024, by and between MEI Pharma, Inc. and David M. Urso | ||||
| 10.4* | Consulting Services Agreement, dated as of August 2, 2024, by and between MEI Pharma, Inc. and Richard G. Ghalie | ||||
| 10.5* | Consulting Services Agreement, dated as of August 2, 2024, by and between MEI Pharma, Inc. and David M. Urso | ||||
| 31.1* | Certification of Principal Executive and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1** | Certification of Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C 1350). | ||||
| 101INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | ||||
| 104 | Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document. |
| * | Filed herewith |
|---|---|
| ** | Furnished herewith |
| + | Portions of this exhibit have been omitted in accordance with Item 601(a)(6) and Item 601(b)(10) of Regulation S-K because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.